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Interactions between kinases and small molecule
inhibitors can be activation state dependent. A
detailed understanding of inhibitor binding therefore
requires characterizing interactions across multiple
activation states. We have systematically explored
the effects of ABL1 activation loop phosphorylation
and PDGFR family autoinhibitory juxtamembrane
domain docking on inhibitor binding affinity. For
a diverse compound set, the affinity patterns
correctly classify inhibitors as having type I or type
II binding modes, and we show that juxtamembrane
domain docking can have dramatic negative effects
on inhibitor affinity. The results have allowed us to
associate ligand-induced conformational changes
observed in cocrystal structures with specific ener-
getic costs. The approach we describe enables
investigation of the complex relationship between
kinase activationstateandcompoundbinding affinity
and should facilitate strategic inhibitor design.INTRODUCTION
Kinases are dynamic proteins that sample a wide range of
conformations, and kinase conformational equilibria are to
a large extent governed by the activation state (Huse and
Kuriyan, 2002). Binding of small molecule inhibitors can be
conformation specific (Schindler et al., 2000), and the nine
ATP-competitive kinase inhibitors currently approved for use in
humans include nearly equal numbers of molecules that bind
to catalytically active and inactive enzyme conformations (Alton
and Lunney, 2008). The effects of activation state on small mole-
cule inhibitor binding affinity have largely been inferred from
structural observations and are only now beginning to be
systematically explored biochemically. To fully characterize the
interaction of inhibitors with their targets, it is necessary to quan-
tify the activation state dependence of inhibitor binding, which
can have important implications for drug discovery (Alton and
Lunney, 2008).
The ABL1-imatinib interaction is perhaps the best understood
example of activation state-dependent inhibitor binding. ABL1,Chemistry & Biology 17, 1241–124like many kinases, is activated in part by activation loop (A-
loop) phosphorylation, which stabilizes a catalytically active
enzyme conformation (Hantschel et al., 2003; Schindler et al.,
2000). Imatinib, however, binds a catalytically inactive conforma-
tion of the ABL1 kinase domain (Nagar et al., 2002) that is disfa-
vored in the phosphorylated, activated state. The activation state
dependence of imatinib binding has been demonstrated in
biochemical studies showing more potent inhibitory activity
against nonphosphorylated relative to phosphorylated ABL1
(Seeliger et al., 2007). The second-generation ABL1 inhibitors
dasatinib and nilotinib are effective against most imatinib-resis-
tant ABL1 variants (Shah et al., 2004; Weisberg et al., 2005).
Nilotinib, like imatinib, is a ‘‘type II’’ inhibitor (Weisberg et al.,
2005) defined by a binding mode that features penetration into
an ‘‘allosteric’’ binding pocket adjacent to the ATP site, acces-
sible when the A-loop adopts a ‘‘DFG-out’’ inactive conformation
(Liu and Gray, 2006), as well as overlap with the ATP site itself.
Based upon this conserved binding mode and the available
biochemical data, type II inhibitor binding is believed to be sensi-
tive to A-loop phosphorylation (Okram et al., 2006). Conversely,
dasatinib is a ‘‘type I’’ inhibitor, defined by a binding mode over-
lapping the ATP site with no penetration into the allosteric pocket
(Tokarski et al., 2006). Type I inhibitors typically do not require
a DFG-out conformation for binding, and structural and
modeling studies suggest that type I inhibitor binding is compat-
ible with multiple A-loop conformations (Nagar et al., 2002;
Tokarski et al., 2006; Vogtherr et al., 2006), including the
‘‘DFG-in’’ active conformation. For this reason, it is believed
that type I inhibitor binding is not generally sensitive to A-loop
phosphorylation (Okram et al., 2006).
The kinase activation state can also be governed by interac-
tions with regulatory domains. The PDGFR family class III
receptor tyrosine kinases (RTKs) CSF1R, FLT3, KIT, and
PDGFRa/b, for example, contain a conserved autoinhibitory jux-
tamembrane (JM) domain that docks with the kinase domain to
stabilize a catalytically inactive DFG-out A-loop conformation
(Griffith et al., 2004; Mol et al., 2004; Schubert et al., 2007).
The JM domain is located between the transmembrane and
kinase domains and contains tyrosine phosphorylation sites
required for enzyme activation (Hubbard, 2004). The PDGFR
family RTKs can exist in at least three distinct activation states
(DiNitto et al., 2010): (1) the ‘‘autoinhibited,’’ nonphosphorylated
state, where the autoinhibited conformation (JMdomain docked)
predominates; (2) the ‘‘nonautoinhibited’’ state, where the JM
domain is phosphorylated and the nonautoinhibited9, November 24, 2010 ª2010 Elsevier Ltd All rights reserved 1241
Figure 1. Activation State-Specific ABL1
Assays Functionally Classify Type I and
Type II Inhibitors
(A) Western blots comparing A-loop p-Y393 levels
(upper) and overall p-Tyr levels (middle) for ABL1
produced with (np-ABL1) or without (p-ABL1)
endogenous phosphatase treatment. ABL1
(Y393F) was prepared identically to p-ABL1. Total
recombinant ABL1 levels (lower) and results for
nontransfected HEK293 cells (lane 1) are indi-
cated.
(B) Kd measurements for the interactions of imati-
nib and dasatinib with np-ABL1, p-ABL1, and
ABL1(Y393F). Assay signals were normalized to
facilitate comparison.
(C) For a series of known and predicted type I and
type II inhibitors, the phosphorylated (Phos.) to
nonphosphorylated (Nonphos.) state Kd ratios
are shown for ABL1 and ABL1(H396P). Values
>1 indicate preferential affinity for the nonphos-
phorylated state. Error bars are the standard devi-
ations of the Kd ratios. Individual Kds are shown in
Table S1.
(D) Same as (C), except that Kd ratios are shown
for ABL1(T315I). For AC220, the Kd for np-ABL1
(T315I) was 3.7 mM, while the Kd for p-ABL1
(T315I) was above the solubility limit (10 mM) and
estimated as 30 mM for the Kd ratio calculation.
See Table S2 and Figure S2.
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‘‘activated’’ state, where the nonautoinhibited state is addition-
ally phosphorylated on the A-loop, and the DFG-in conformation
is stabilized. Ligand binding to the extracellular domain of the
autoinhibited enzyme induces dimerization and trans-autophos-
phorylation of the JM domain, which disrupts interactions with
the kinase domain (Mol et al., 2004), effecting a shift to the non-
autoinhibited state. The A-loop is subsequently phosphorylated
to produce the activated state, which, for KIT, has similar cata-
lytic activity to the nonautoinhibited state (DiNitto et al., 2010).
The autoinhibitory function of the JM domain can also be disrup-
ted by mutations, and kinases harboring such activating
mutations often drive disease and are targets for kinase inhibitor
therapy (Janne et al., 2009). The autoinhibited structures of
CSF1R, FLT3, and KIT (Griffith et al., 2004; Mol et al., 2004;
Schubert et al., 2007) suggest that JM domain docking is
energetically favorable and likely to impact inhibitor binding.
Cocrystal structures have revealed a range of inhibitor binding
modes that are either largely compatible or incompatible with
the autoinhibited conformation (Gajiwala et al., 2009; Mol et al.,
2004; Schubert et al., 2007). The structures show that inhibitor
binding induces conformational changes relative to the apo-
autoinhibited structure, but the associated energetic costs for
these changes have not been defined.
Novel binding assays using kinases modified on the A-loop
with fluorescent tags have been reported that can identify inhib-
itors as having DFG-out bindingmodes, but the effects of activa-
tion state on inhibitor binding are just beginning to be explored in
this system (Simard et al., 2009). Enzymatic studies on KIT show
that A-loop phosphorylation can significantly affect inhibitor
potency, but the impact of JM domain docking on inhibitor
binding has not been directly addressed (DiNitto et al., 2010).1242 Chemistry & Biology 17, 1241–1249, November 24, 2010 ª2010Here, we systematically and quantitatively measure activation
state-dependent inhibitor binding affinity in the context of both
ABL1 A-loop phosphorylation and JM domain-mediated autoin-
hibition for class III RTKs.
RESULTS
Inhibitor Binding Assays for ABL1 Differentially
Phosphorylated on the A-loop
To systematically measure the effects of ABL1 A-loop phosphor-
ylation on small molecule inhibitor binding affinity, we developed
competition binding assays (Karaman et al., 2008). Activation
state-specific binding assays do not require catalysis and there-
fore avoid several problematic aspects of enzyme activity
assays, including reduced catalytic activity of the unactivated
state, confounding activation of the unactivated state during
the assay, and state-dependent Km(ATP) values. Binding assays
may thus provide a more general approach than activity assays
to explore activation state-dependent inhibitor binding. The
ABL1 kinase domain was expressed in HEK293 cells, and
extracts were prepared under conditions that either preserved
or greatly reduced A-loop phosphorylation. The A-loop contains
a single Tyr residue (Y393), and a western blot with a p-Y393
antibody confirmed that the two kinase preparations had large
differences in phosphorylation at this site (Figure 1A, upper,
compare lanes 2 and 3). The nonphosphorylatable ABL1
(Y393F) mutant lacked any p-Y393 signal, as expected (lane 4).
In contrast, blots probed with a general p-Tyr antibody showed
that overall p-Tyr levels were similar for the phosphorylated
A-loop (p-ABL1) and ABL1(Y393F) preparations (Figure 1A,
middle) and were moderately reduced in the nonphosphorylated
A-loop preparation (np-ABL1). Imatinib binding affinity wasElsevier Ltd All rights reserved
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constants (Kds) of imatinib for np-ABL1 and ABL1(Y393F) were
nearly identical and more than 30-fold lower than the Kd for
p-ABL1 (Figure 1B; see Table S1 available online), consistent
with the results from enzyme activity assays (Seeliger et al.,
2007). In contrast to imatinib, the affinities of the type I inhibitor
dasatinib for np-ABL1, ABL1(Y393F), and p-ABL1 were nearly
identical (Figure 1B; Table S1). Taken together, these immuno-
blot and Kd data strongly suggest that the assays specifically
query the effects of A-loop phosphorylation on inhibitor binding
affinity, though we cannot completely rule out the involvement
of p-Tyr residues at other sites.
Distinguishing Type I from Type II Inhibitors
Binding affinity dependent on the phosphorylation state of the
ABL1 A-loop may be a general feature of type II inhibitors that
offers an approach to functionally classify compounds as type
I or type II in the absence of structural information (Okram
et al., 2006). To determine how predictive such an approach
may be, we measured binding constants for an additional set
of known or predicted type I and type II inhibitors for p-ABL1
and np-ABL1 (Table S2). The compounds tested included known
ABL1 inhibitors and compounds that are not primarily ABL1
inhibitors, but for which activity against ABL1 has been demon-
strated (Carter et al., 2005; Karaman et al., 2008). Nilotinib is
a structurally confirmed type II inhibitor (Weisberg et al., 2005),
and PD-173955 (Nagar et al., 2002) and VX-680 are structurally
confirmed type I inhibitors (Table S2). AST-487 has been hypoth-
esized to be a type II inhibitor based on molecular modeling, and
modeling studies also suggest that SKI-606 is a type I inhibitor
(Table S2). Sunitinib is an interesting type I inhibitor that has
been observed to bind KIT in an autoinhibited, DFG-out confor-
mation but does not penetrate into the allosteric pocket
(Gajiwala et al., 2009).
Imatinib and the predicted type II inhibitor AST-487 exhibited
a clear preference (>30-fold) for np-ABL1, while nilotinib showed
only a small preference (Figure 1C; Table S1). In contrast, the
type I inhibitors did not bind preferentially to either form of the
kinase (Figure 1C; Table S1). To determine if the relative affinity
patterns observed for wild-type ABL1 are retained in an imati-
nib-resistant mutant variant, we developed assays for ABL1
(H396P) differentially phosphorylated on the A-loop. The results
for ABL1(H396P) were similar to wild-type, with the exception
that nilotinib was clearly identified as a type II inhibitor, with
a 10-fold preference for the nonphosphorylated state (Figure 1C;
Table S1). Thus, together the wild-type and H396P mutant
assays correctly identify or confirm inhibitor type across this
compound set.
To explore how broadly this approach can be applied, we at-
tempted to classify compounds that not only are not primarily
ABL1 inhibitors, but that also lack potent binding affinity for
wild-type ABL1. We developed assays for the drug-resistant
ABL1(T315I) mutant, which binds some inhibitors with higher
affinity than wild-type ABL1 (Karaman et al., 2008). BIRB-796
is a confirmed type II p38a inhibitor (Pargellis et al., 2002), while
AC220 is a second-generation FLT3 inhibitor with an undefined
binding mode (Table S2) (Zarrinkar et al., 2009). AC220 and
BIRB-796 have been shown to bind with modest or moderate
affinity to ABL1(T315I), respectively, but were poorly detectedChemistry & Biology 17, 1241–124in wild-type ABL1 assays (Carter et al., 2005; Zarrinkar et al.,
2009). Markedly higher affinity was observed for both
compounds for np-ABL1(T315I) relative to p-ABL1(T315I) (Fig-
ure 1D; Table S1), correctly identifying BIRB-796 as a type II
inhibitor, and suggesting that AC220 is a type II inhibitor as
well. To determine whether the T315I mutation itself affects the
observed binding mode, we tested compounds whose binding
affinity relative to wild-type is impacted by this mutation either
dramatically (nilotinib, dasatinib, PD-173955), modestly
(AST-487), orminimally (VX-680, sunitinib). In all cases, the phos-
phorylation state dependence of binding affinity was qualitatively
the same as for wild-type ABL1 and ABL1(H396P) (Figure 1D;
Table S1), and nilotinib was again correctly classified as a type
II inhibitor. Thus, the binding mode classifications are consistent
across the ABL1 variants tested and are independent of the
affinity for a particular ABL1 variant.
These results demonstrate that a suite of activation state-
specific ABL1 assays can be used to classify the type I/type II
binding mode of inhibitors, including those that primarily target
kinases other than ABL1. The consistent trends across multiple
ABL1 variants provide added confidence in the classification,
as exemplified by nilotinib, where the wild-type ABL1 data alone
were equivocal, while data across the full assay suite clearly and
correctly identified the type II bindingmode. Since the type I/type
II inhibitor binding mode is, with rare exceptions (Atwell et al.,
2004), generally conserved across kinases (Mol et al., 2004;
Namboodiri et al., 2010; Seeliger et al., 2007), we suggest that
this approach is informative for a wide range of kinase inhibitors,
particularly since ABL1 is a common off-target of compounds
that primarily target other kinases (Karaman et al., 2008).
Differential Binding of Both Type I and Type II Inhibitors
to Autoinhibited and Nonautoinhibited States of FLT3,
KIT, and CSF1R
Tomeasure the effects of JM domain docking on inhibitor affinity
for FLT3, KIT, and CSF1R, we developed binding assays for
autoinhibited and nonautoinhibited states of each kinase. The
JM domain comprises three short motifs, JM-B (‘‘binding’’),
JM-S (‘‘switch’’), and JM-Z (‘‘zipper’’) (Figure 2A) (Griffith et al.,
2004). JM-B closely interacts with multiple key regions of the
active site in the autoinhibited conformation, whereas JM-S is
a b twist containing tyrosine phosphorylation sites required to
switch the enzyme to the nonautoinhibited state, and JM-Z is
a linker associated with the N-terminal lobe that positions JM-
S and JM-B in the correct register for autoinhibition (Griffith
et al., 2004). In a structure of nonautoinhibited KIT di-phosphor-
ylated on JM-S, both JM-B and JM-S are disordered, whereas
JM-Z remains ordered and associated with the N-terminal lobe
(Mol et al., 2004). To develop assays for the autoinhibited state,
we therefore expressed each enzyme with an intact JM domain
(JMplus), and to develop assays for the nonautoinhibited state,
we expressed truncated proteins lacking JM-B and JM-S, but
including JM-Z (JMminus) (Figure 2A). We then measured the
binding affinities of several known or predicted type I and type
II inhibitors for autoinhibited and nonautoinhibited FLT3, KIT,
and CSF1R. For each enzyme, the inhibitor panel included well
established inhibitors of the kinase being queried as well as
compounds optimized for other kinases that have a broad range
of affinities for the queried kinase. Type I inhibitors not tested9, November 24, 2010 ª2010 Elsevier Ltd All rights reserved 1243
Figure 2. JMDomain Docking Substantially
Impacts Inhibitor Binding Affinity for the
Class III RTKs KIT, FLT3, and CSF1R
(A) Alignment of the conserved KIT, CSF1R, and
FLT3 JM domains showing the constructs used.
The N termini of the autoinhibited (JMplus) and
nonautoinhibited (JMminus) constructs are indi-
cated, as are the positions of the KIT V559D and
FLT3 ITD mutations. Both mutations are in the
context of JMplus constructs, and the ITD muta-
tion is described in Supplemental Experimental
Procedures. The JM domain submotifs (Griffith
et al., 2004) and the start of the kinase domain
(KD) are indicated.
(B) Relative binding affinities of known or pre-
dicted type I and type II inhibitors for autoinhibited
and nonautoinhibited KIT and KIT(V559D). To
facilitate visualization of affinity offsets between
activation states, the data have been normalized
to the Kd values for the nonautoinhibited state.
Normalized Kd values of 1 indicate the affinity is
equal to that for the nonautoinhibited state, and
values >1 indicate a reduced affinity relative to
the nonautoinhibited state. Kd values for the non-
autoinhibited state spanned several orders of
magnitude. To simplify comparison, we assigned
each inhibitor to a ‘‘Kd bin’’ based on its affinity for
the nonautoinhibited state (shown below chart):
bin 1 - Kd = 0.01–0.1 nM; bin 2 - Kd = 0.1–
1.0 nM; bin 3 - Kd = 1–10 nM; bin 4 - Kd = 10–
100 nM; bin 5 - Kd = 100–1000 nM; bin 6 - Kd =
1000–10,000 nM. Error bars are the standard
deviations of the normalized Kds. Individual Kds
are shown in Table S1.
(C) and (D) Same as (B), except that normalized
Kds are shown for FLT3 and CSF1R assays,
respectively. See also Table S2 and Figure S1.
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ine (STAUR) and its analogs PKC-412 and CEP-701, and
additional known type II inhibitors included the VEGFR2 inhibitor
sorafenib and the CSF1R inhibitor GW-2580 (Table S2). Pre-
dicted type II inhibitors not tested against the ABL1 assays
included the VEGFR2 inhibitor PTK-787, which is related to
a known type II inhibitor, as well as Ki-20227 and MLN-518,
which have type II-like chemical structures and target CSF1R
and FLT3, respectively (Table S2). Inhibitor binding affinity was
consistently and in many cases dramatically reduced by JM
domain docking for all three RTKs, with most inhibitors having
10- to 1000-fold greater affinity for the nonautoinhibited state
relative to the autoinhibited state (Figures 2B–2D; Table S1).
These affinity shifts were apparent for both type I and type II
inhibitors, unlike for ABL1, where only type II inhibitor affinity
was activation state dependent. The magnitude of the affinity
shift between nonautoinhibited and autoinhibited states was
not dependent on the absolute affinity of compounds for the non-
autoinhibited state, with both high affinity and low affinity
compounds exhibiting a range of affinity shifts (see ‘‘Kd bins’’1244 Chemistry & Biology 17, 1241–1249, November 24, 2010 ª2010 Elsevier Ltd All rights rebelow charts in Figures 2B–2D; Table
S1). For KIT and FLT3, type I inhibitors
had affinity shifts of 10- to 100-fold,
whereas for type II inhibitors the effectswere larger (100- to 1000-fold). For CSF1R the affinity shifts for
type II inhibitors were more compound dependent, and the two
compounds optimized for CSF1R inhibition, GW-2580 and Ki-
20227, had only az10-fold preference for the nonautoinhibited
state, whereas up to 1000-fold affinity differences were
observed for AST-487, imatinib, and PTK-787. Autoinhibited
CSF1R was also uniquely tolerant of type I inhibitor binding,
with most affinity shifts %10-fold, including two compounds,
PKC-412 and sunitinib, that did not significantly discriminate
between activation states. One explanation for the reduced
type I inhibitor affinity shifts for CSF1R is that its docked JM
domain may permit more flexibility within the ATP site than the
docked KIT and FLT3 JM domains. The overall JM domain dock-
ing energies for these kinases may be similar, however, since for
all three enzymes, affinity shifts of 1000-fold were observed for
imatinib and/or AST-487, which are known or expected to induce
undocking of the JM domain upon binding, respectively. These
data establish that the activation state for these RTKs can
have a large impact on both type I and type II inhibitor affinity,
but that some potent inhibitors have similar affinities for bothserved
Table 1. Kd Values for ATP Binding to Autoinhibited,
Nonautoinhibited, and Mutant Forms of CSF1R, FLT3, and KIT
Kinase Activation State
Kd ATP
(mM)a
CSF1R Autoinhibited >1000
Nonautoinhibited 16 ± 6.1
FLT3 Autoinhibited >1000
Nonautoinhibited 7.0 ± 2.3
ITD 75 ± 22
KIT Autoinhibited >1000
Nonautoinhibited 180 ± 58
V559D 100 ± 13
See also Figure S1.
a Values are the average of at least four measurements ± SD.
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affinity preference for the autoinhibited state, and the design of
compounds with this profile presents a compelling medicinal
chemistry challenge.
Tumorigenic Activating Mutations in the JM Domains of
KIT and FLT3 Relieve Autoinhibition to Different Extents
To determine the effect of activating tumorigenic mutations
known to interfere with JM domain docking, we also developed
assays for FLT3 harboring an internal tandem duplication (ITD),
known to be a driver mutation in AML (Meshinchi and Appel-
baum, 2009), and for KIT harboring a V559D mutation, known
to be a driver mutation in gastrointestinal stromal tumors (Hein-
rich et al., 2008) (Figure 2A). The activating mutations markedly
increased inhibitor binding affinity relative to the autoinhibited
state, a result consistent with these mutations disrupting JM
domain docking (Figures 2B and 2C; Table S1). The KIT
(V559D) data were nearly identical to the nonautoinhibited,
JMminus data, suggesting that this mutation is fully penetrant
and functionally equivalent to a JM-B/JM-S deletion (Figure 2B).
In contrast, the FLT3(ITD) mutation was not fully penetrant, with
the type II inhibitors still showingz10-fold binding affinity pref-
erences for the nonautoinhibited state (Figure 2C; Table S1).
The particular ITD used in our constructs is an insertion between
the JM-Z and JM-S motifs that is likely to have unfavorable
entropic consequences for JM domain docking, but unlikely to
directly disrupt JM-B and JM-S (Figure 2A), which could explain
the lack of full penetrance. Conversely, the KIT V559D mutation
is within the critical JM-B motif and likely disrupts docking
directly (Figure 2A). Thus, these data also provide information
about protein structure and stability, where the inhibitors probe
the energetic consequences of activating mutations.
ATP Binding Affinity is Activation State Dependent
for KIT, FLT3, and CSF1R
ATP binding affinity is a key parameter that governs the effective
cellular potency of ATP-competitive small molecule kinase inhib-
itors. To determine the activation state dependence of ATP
binding, we measured ATP affinity for each of the autoinhibited,
nonautoinhibited and mutant enzyme forms. No binding was
detected at 1 mM ATP for any of the autoinhibited states, while
the Kd for ATP was in the 10–200 mM range for the nonautoinhi-Chemistry & Biology 17, 1241–124bited states (Table 1). As was observed for inhibitor binding, the
KIT(V559D) mutant behaved identically to the nonautoinhibited
state, and the FLT3(ITD) mutant had an intermediate affinity,
consistent with full and partial release of autoinhibition for these
mutants, respectively. The autoinhibited state is thus not antici-
pated to significantly bind ATP at physiological concentrations,
whichmakes it an attractive target forATP-competitive inhibitors.
Further Characterization and Validation of the
Activation State-Specific RTK Inhibitor Binding Assays
During this study we further characterized and validated the
autoinhibited, nonautoinhibited, and mutant RTK assays in three
ways. First, to ensure that any low level of autophosphorylation
occurring during protein expression was not a confounding
factor, we also tested kinase preparations made by treating
the HEK293 cells with potent inhibitors during protein expres-
sion, which reduced p-Tyr levels by R80% (see Supplemental
Experimental Procedures). For all but one assay, nearly identical
compound binding affinity data were measured for kinases
prepared in the presence or absence of inhibitor, demonstrating
that the autoinhibited assays query the fully autoinhibited state
and that any low level of JM domain or A-loop phosphorylation
was not impacting the results for the nonautoinhibited and
mutant assays (Table S1). These results confirm that the assays
exclusively address the effects of JM docking on inhibitor
binding and not the effects of downstream A-loop phosphoryla-
tion. The lone exception was the autoinhibited CSF1R assay,
where the Kd values for some type II inhibitors were marginally
increased for the inhibitor-treated preparation relative to the
standard preparation (Table S1). For this reason, the autoinhi-
bited CSF1R data described above were all measured for the
inhibitor-treated enzyme preparation, ensuring that the fully
autoinhibited state was queried. Second, to further confirm
that the JMminus constructs were an appropriate surrogate for
the nonautoinhibited state, we measured cellular IC50s for
several inhibitors against ligand-stimulated KIT. Across nine
inhibitors, the nonautoinhibited Kd and cellular IC50 rank orders
were nearly identical, with imatinib being the lone exception
(Figure S1). The nonautoinhibited Kds were generally about
10-fold lower than the cellular IC50s, an offset likely due to
competition with ATP in the cellular milieu (Table 1). In contrast,
the autoinhibited Kd values were generallyR10-fold higher than
the cellular IC50 values, consistent with the nonautoinhibited
state being queried in the ligand-stimulated cellular assay. Third,
we tested imatinib, sunitinib, and dasatinib in KIT enzyme activity
assays performed by three commercial vendors. KIT constructs
including the JM domain were used for these assays, and in all
cases the in vitro IC50 values were R10-fold higher than the
cellular IC50 values, and closer to the autoinhibited state Kds
than to the nonautoinhibited state Kds (Figure S1). These data
suggest that the enzyme preparations were at least partially
autoinhibited. In support of this hypothesis, additional tests in
a commercial assay for KIT harboring an activating JM domain
mutation (V560G) yielded IC50 values for all three inhibitors that
were R100-fold lower than the values measured for wild-type
KIT (data not shown). Overall, these results support the use of
JMminus constructs as surrogates for the nonautoinhibited
state, and both our results and results from others (DiNitto
et al., 2010) suggest that in vitro enzyme activity data for these9, November 24, 2010 ª2010 Elsevier Ltd All rights reserved 1245
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vation state is not clearly defined.
DISCUSSION
ABL1 Activation State-Dependent Binding Functionally
Classifies Inhibitor Binding Mode
Determining ABL1 activation state-specific binding affinity can
classify inhibitors as having type I or type II binding modes in
the absence of cocrystal structures. Importantly, correct classi-
fications are made for inhibitors that primarily target kinases
other than ABL1, suggesting that this approach would be of
general utility in kinase inhibitor discovery. This albeit low resolu-
tion structural classification is relevant since important drug-like
properties of kinase inhibitors are likely affected by this param-
eter, including kinome selectivity (Schindler et al., 2000), target
residence time (Pargellis et al., 2002), and affinity for enzyme
conformations relevant to specific disease indications (Gajiwala
et al., 2009; Shah et al., 2004). It is thus likely that the optimal
binding mode shall be both kinase and indication specific. For
example, type I inhibitors can have clear advantages over type
II inhibitors in diseases driven by kinases that harbor activating
and resistancemutations that significantly stabilize the enzyme’s
active conformation (DiNitto et al., 2010; Gajiwala et al., 2009;
Shah et al., 2002, 2004). Since the optimal inhibitor binding
mode is often unknown at the outset of a discovery program, it
can be helpful to identify a set of lead compounds that includes
both type I and type II inhibitors. A data-driven determination of
the ideal inhibitor type can then proceed during lead optimiza-
tion, based on performance in downstream assays. Activation
state-specific assays should facilitate this strategic approach,
particularly in the context of high-throughput, multikinase
profiling initiatives across multiple chemical series (Goldstein
et al., 2008).
The Energetic Consequences of ABL1 A-loop
Phosphorylation on Type I and Type II Inhibitor Binding
While type II inhibitors exhibited a consistent preference for the
nonphosphorylated state of ABL1, the effect of phosphorylation
was generally moderate (10- to 30-fold). These data suggest that
sampling of the DFG-out A-loop conformation is not dramati-
cally reduced upon activation, which highlights the important
distinction between activation state and conformational state,
since activated enzymes nevertheless sample inactive confor-
mations. There are few examples apart from the ABL1-imatinib
interaction where the effects of A-loop phosphorylation on inhib-
itor binding have been systematically addressed (Hantschel
et al., 2003; Seeliger et al., 2007), but the effects are likely to
be kinase specific. For example, while inhibitor binding to KIT
was dramatically affected by A-loop phosphorylation (DiNitto
et al., 2010), no effects on type II inhibitor binding were observed
for p38a (Sullivan et al., 2005). None of the type I inhibitors ex-
hibited a significant activation state preference (Figures 1C
and 1D; Table S1), and there are at least two possible explana-
tions for this result. One explanation is that type I inhibitors are
tolerant of conformational variability and bind equally well to
multiple active-like and inactive conformations (Figure S2C) (Na-
gar et al., 2002; Shah et al., 2004; Tokarski et al., 2006; Vogtherr
et al., 2006). This hypothesis would require that all of the type I1246 Chemistry & Biology 17, 1241–1249, November 24, 2010 ª2010inhibitors are equally tolerant of conformational variability,
which, given the chemical diversity within this set (Table S2),
would seem unlikely. A nonmutually exclusive explanation is
that, even for the nonphosphorylated state, ABL1 exists
primarily in an active-like conformation, a hypothesis consistent
with the high catalytic activity of the nonphosphorylated ABL1
kinase domain (Schindler et al., 2000). For this thermodynamic
model, the apparent Kd values for type I inhibitor binding are
independent of the phosphorylation state, regardless of the
tolerance for conformational variability (Figure S2B). NMR
studies have shown that dasatinib binds an active-like confor-
mation of nonphosphorylated ABL1 (Vajpai et al., 2008) and
suggest that a DFG-in A-loop conformation may be obligatory
for binding, which would predict an enhanced affinity for
p-ABL1 relative to np-ABL1.We observe, however, that dasatinib
binding affinity is not activation state dependent (Figures 1B–1D;
Table S1), which may suggest that both ABL1 activation states
primarily sample active-like conformations, as discussed above
(Figure S2B). Additional structural studies on apo-ABL1 are
required to further define the A-loop conformation(s) required
for dasatinib binding, and we emphasize that activation state-
independent binding does not necessarily prove a lack of
conformation-specific binding. In contrast to dasatinib, sunitinib
is a type I inhibitor shown to have an apparent obligatory DFG-
out binding mode for autoinhibited KIT (Gajiwala et al., 2009) and
would thus be expected to have an affinity preference for np-
ABL1 similar to type II inhibitors (Figure S2A). We show,
however, that sunitinib binding is not activation state dependent
(Figures 1C and 1D; Table S1). One possible explanation for this
disconnect is that sunitinib has different binding modes for ABL1
and KIT, with only KIT requiring the DFG-out A-loop conforma-
tion. In support of this hypothesis, cocrystal structures of inhib-
itors related to sunitinib bound to FGFR1 reveal a DFG-in
binding mode (Mohammadi et al., 1997).
Activation State-Dependent Binding Affinity Measures
the Degree of Conformational Change Induced by
Inhibitor Binding to Autoinhibited Class III RTKs
In the autoinhibited state, the docked JM domain can interfere
with inhibitor binding in two ways: first, by sterically clashing
with the inhibitor directly, and, second, by stabilizing an enzyme
conformation incompatible with inhibitor binding. Relative
affinity preferences for the nonautoinhibited state likely reflect
the degree to which the autoinhibited conformation must be
disrupted to accommodate inhibitor binding. A crystal structure
of imatinib bound to KIT (PDB ID 1T46) (Mol et al., 2004) has
shown that binding is sterically incompatible with docking of
the JM domain, whereas a crystal structure of sunitinib bound
to KIT has revealed a binding mode compatible with a docked
JM domain (PDB ID 3G0E) (Gajiwala et al., 2009). These struc-
tures are consistent with the much larger affinity preferences
for the nonautoinhibited state observed here for imatinib
compared with sunitinib. Similarly, a crystal structure of the
type II inhibitor GW-2580 bound to autoinhibited CSF1R shows
only minor conformational changes relative to the apo-autoinhi-
bited structure (Shewchuk et al., 2004), consistent with the rela-
tively small affinity preference for the nonautoinhibited state
measured here. In some cases, type I inhibitors, which should
not sterically clash with a docked JM domain, nevertheless areElsevier Ltd All rights reserved
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type II inhibitors, likely due to a requirement for rearrangements
of the DFG triad and the P loop, which are held in position by the
JM domain (Griffith et al., 2004). Indeed, cocrystal structures of
type I inhibitors bound to autoinhibited CSF1R show a range of
conformational changes in the binding site relative to the apo-
structure, yet the JM domain remains docked (Huang et al.,
2008, 2009; Schubert et al., 2007). Interestingly, a recent crystal
structure has shown that binding of a type I inhibitor can induce
undocking of the JM domain, presumably by forcing the A-loop
into a DFG-in conformation (Meyers et al., 2010). Thus, inhibitor
binding may also potentially undock the JM domain by an allo-
steric mechanism, even in the absence of direct steric clashes.
Large affinity preferences for the nonautoinhibited state, similar
to imatinib, would be predicted for inhibitors acting through
this mechanism.
A recent model for KIT activation based on enzyme activity
data proposes that the autoinhibited state is sensitive to imatinib
(DiNitto et al., 2010), which is inconsistent with the results shown
here. One explanation for this apparent discrepancy may be the
difficulty of directly querying the low activity, autoinhibited state
with enzyme activity assays. Our results do support the hypoth-
esis that dasatinib binding is conformationally tolerant (Tokarski
et al., 2006), since only a small preference for the nonautoinhi-
bited state was measured. If dasatinib binding strictly required
a DFG-in A-loop conformation, a much larger preference would
be expected. The data therefore suggest that dasatinib binding
is largely compatible with the DFG-out A-loop conformation
that predominates in the autoinhibited state.
When combined with structural data, these biochemical data
can estimate the energetic ‘‘price tags’’ for specific perturba-
tions to the apo-autoinhibited structure that are induced upon
inhibitor binding. This may be valuable for structure-guided
drug design and for molecular modeling in general. Even in the
absence of crystal structures, activation state-specific binding
data can provide structure-function information that character-
izes both type I and type II inhibitors based on their compatibility
with the autoinhibited conformation. In principle, the data could
be used during lead optimization to monitor the impact of chem-
ical changes on detailed inhibitor binding mode. Since PDGFR
family kinases are commonly observed off-targets (Karaman
et al., 2008), the approach should also be useful for character-
izing inhibitors primarily targeting kinases from other classes.
The energetic penalties associated with conformational
changes to the autoinhibited structure are surprisingly large.
Thez1000-fold affinity preference of imatinib for the nonautoin-
hibited state suggests that undocking of the JM domain has
a cost ofz3.5 kcal/mol. Even minor perturbations to the autoin-
hibited conformation can have a significant energetic cost. For
example, sunitinib is known to induce only a minor repositioning
of the DFG triad upon binding to autoinhibited KIT (Gajiwala
et al., 2009), but nonetheless has a 30-fold affinity preference
for the nonautoinhibited state. These findings illustrate how
biochemical data can be used to interpret structural data, which
do not provide quantitative thermodynamic information. Further-
more, the results differentiate JM domain mutations based on
their relative ability to relieve autoinhibition, suggesting that the
structural consequences of activating mutations can be inferred
from these types of data.Chemistry & Biology 17, 1241–124Activation State-Dependent Inhibitor Binding to PDGFR
Family RTKs: Implications for Drug Discovery
Small molecule kinase inhibitors should ideally target the
disease-driving activation state and any additional states known
to be induced by acquired resistance mutations. For diseases
driven by kinases harboring JM domain mutations, the nonau-
toinhibited state is the relevant target initially, but second site
A-loopmutations can emerge during treatment that confer inhib-
itor resistance by effecting a shift to the activated state (DiNitto
et al., 2010; Gajiwala et al., 2009). Next-generation inhibitors
should therefore target both the nonautoinhibited and activated
states, in contrast to imatinib and sunitinib, which lack potency
against the activated state (DiNitto et al., 2010). For diseases
driven by mutant kinases, the autoinhibited state is less relevant
and should be avoided to minimize any undesired effects on
normal cells. Conversely, for diseases driven by a wild-type
enzyme, the autoinhibited state may be an attractive target for
novel inhibitor discovery: this state lacks significant ATP affinity,
which should enhance cellular inhibitor potency; and the docked
JM domain may provide additional diversity within the binding
site, facilitating the design of inhibitors having novel and selec-
tive inhibition profiles.SIGNIFICANCE
Kinases exist in multiple activation states that govern the
enzymes’ conformational ensemble, and small molecule
binding can be activation state dependent. The effects of
activation state on inhibitor binding, however, are just begin-
ning to be explored systematically. Here, for two very
different modes of activation, we have quantitatively and
systematically measured the effects of activation state on
inhibitor binding affinity. Results from phosphorylation
state-specific binding assays for ABL1 have shown that
type II, but not type I, inhibitor binding is activation state
dependent, and that the assays can be used to correctly
classify compounds as having type I or type II binding
modes. Though an inhibitor’s binding mode affects several
properties relevant for drugs, it is often not characterized
due to the requirement for cocrystal structures. The
biochemical approach we describe removes this bottleneck
and should be of great utility in kinase inhibitor discovery.
In a second system exploring the impact of autoinhibitory
JM domain docking on inhibitor binding to PDGFR family
RTKs, a range of effects on binding affinity were observed
for both type I and type II inhibitors. Cocrystal structures
have shown that inhibitor binding induces perturbations to
the autoinhibited conformation ranging in severity from
minor rearrangements of the A-loop to complete undocking
of the JM domain. The energetic costs for these induced
conformational perturbations have not previously been
defined, and the binding results show that these costs scale
with the severity of the induced perturbation. For inhibitors
like imatinib, which induce complete undocking of the JM
domain, the costs can be quite large (z3.5 kcal/mol). The
approach we describe should facilitate structure-guided
drug design and also the strategic optimization of inhibitors
best suited for specific disease indications.9, November 24, 2010 ª2010 Elsevier Ltd All rights reserved 1247
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Inhibitors and Antibodies
See Supplemental Experimental Procedures.
Protein Expression
All enzyme constructs were expressed as N-terminal fusions to the DNA
binding domain of NFkB in transiently transfected HEK293 cells. Detailed
construct information is provided in Supplemental Experimental Procedures.
For the autoinhibited CSF1R construct, transfected cells were treated with
500 nM dasatinib for 1 hr prior to harvest to inhibit activating autophosphor-
ylation. Cell extracts were prepared in M-PER extraction buffer (Pierce) in
the presence of Protease Inhibitor Cocktail Complete (Roche) and Phospha-
tase Inhibitor Cocktail Set II (Merck) per manufacturers’ instructions. Phos-
phatase inhibitors were omitted for the np-ABL1, np-ABL1(H396P), and
autoinhibited CSF1R preparations. For p-ABL1, ABL1(Y393F), p-ABL1
(H396P), and p-ABL1(T315I), phosphatase inhibitors were added 2 hr prior
to cell harvest to further preserve phosphorylation. For np-ABL1 and
np-ABL1(H396P), extracts were incubated for 45 min at 30C, allowing
endogenous phosphatases to dephosphorylate p-Y393. For np-ABL1
(T315I) the construct contained a Y393F mutation to prevent phosphoryla-
tion at this site.
Competition Binding Assays
Inhibitor binding constants were measured by using active site-dependent
competition binding assays essentially as described (Karaman et al., 2008).
In brief, kinases were labeled with a chimeric double-stranded DNA tag con-
taining the NFkB binding site (50-GGGAATTCCC-30) fused to an amplicon for
qPCR readout, which was added directly to the expression extracts. Binding
reactions were assembled by combining DNA-tagged kinase extract, affinity
beads loaded with a kinase inhibitor probemolecule (see Supplemental Exper-
imental Procedures), and test compound in 13 binding buffer (PBS/0.05%
Tween 20/10 mM DTT/0.1% BSA/2 mg/ml sonicated salmon sperm DNA).
Extracts were used directly in binding assays without any enzyme purification
steps at a R10,000-fold overall stock dilution (final DNA-tagged enzyme
concentration <0.1 nM). Assays were incubated for 1 hr at room temperature,
which was sufficient to establish equilibrium. MgCl2 (2 mM) was included in all
ATP binding studies. Subsequent washing, elution, and qPCR readout steps
were as described (Karaman et al., 2008). For each assay the affinity probe
concentrations were optimized to ensure that true thermodynamic inhibitor
Kd values were measured, as described in Supplemental Experimental
Procedures.
Error Analysis
All reported Kd values are the average of at least fourmeasurementsmade in at
least two separate experiments. Standard deviations are reported in Table S1,
and coefficients of variation were generallyz20%. For Kd ratios (Figure 1) and
normalized Kds (Figure 2), propagated errors for quotients were calculated by
using the equation:
ðX1±S1Þ=ðX2±S2Þ= ðX1=X2Þ± ðX1=X2Þ

ðS1=X1Þ2 + ðS2=X2Þ2
0:5
;
where X and S are averages and standard deviations, respectively.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
two figures, and two tables and can be found with this article online at
doi:10.1016/j.chembiol.2010.09.010.
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